Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME2S4D)

Drug Name

JNJ-61393215 Drug Info

Synonyms

Q66977422

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Orexin receptor type 1 (HCRTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SB-649868	DMYLBOU	Insomnia	7A00-7A0Z	Phase 2	[3]
AZD4041	DMEPQI4	Opioid use disorder	6C43.2Z	Phase 1	[4]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 8	DM7JX8U	N. A.	N. A.	Patented	[5]
1,2-diamino cyclopentane-based derivative 26	DMTFG4J	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04080752) A Study of JNJ-61393215 in the Treatment of Depression. U.S. National Institutes of Health.
2	Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	Clinical pipeline report, company report or official report of AstraZeneca
5	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.